Amniotics™

Amniotics AB is a biopharmaceutical company dedicated to providing unique stem cell therapeutics to patients in need.

 

Our Technology

Amniotics™ has developed a unique pipeline of cell therapeutics combining the desirable properties of neonatal source and tissue specificity. Our product is tailored to the organ of choice (such as e.g. lung, kidney, or CNS/brain). Our technology combines unique properties of neonatal cells with tissue-relevance, making it possible to treat corresponding tissues.

A Novel Source

Our cells originate from full term amniotic fluid, collected at planned cesarean and processed with our technology which ensures the properties are ideal for regenerative and immunomodulatory medicine. We have developed a proprietary method and a device for the extraction (according to GMP protocols) and use of the amniotic fluid material.

Harvesting nature’s powers

Mesenchymal stem cells (MSCs) have been shown to aid in healing damaged organs and tissues, and to modulate deleterious inflammatory processes in a wide spectrum of diseases that have a high unmet medical need. With our technology, we tap straight into the healing properties provided by tissue-relevant neonatal stem cells.

In the News

Unique stem cells from amniotic fluid (article in Swedish)

Unique stem cells from amniotic fluid (article in Swedish)

The biotech company Amniotics has developed technologies for extracting and refining amniotic fluid stem cells for cutting-edge therapy methods. In 2020, the company will enter the clinical phase, which may lead to a breakthrough in future cell therapies. https://www.di.se/brandstudio/amniotics/unika-stamceller-ur-fostervatten/

read more

What happens in Swedish virus research?

The Bridge & Medicon Village arranged a #iställetföralmedalen digital event on work & health. https://altitudemeetings.se/jobb-halsa/ Amniotics CEO Kåre Engilde participated in discussions on Swedish virus research. https://vimeo.com/431809235

COVID19 – The Corona virus pandemic calls us to action

Amniotics AB is uniquely positioned to, and we believe it is our duty to, explore a novel treatment modality for severe respiratory issues related to infections from the corona virus SARS-CoV-2. Our research and development program over the last decade geared towards treatment of severe  respiratory diseases has created the knowledge and experience that may be applied to treating respiratory issues associated with COVID19. The severity of the most affected patients calls us to action. We are answering that call.

WP to LinkedIn Auto Publish Powered By : XYZScripts.com